loading

INVITRO SALES, CASH INCREASE AGAIN; MERGER PLANS UPDATE

W. Richard Ulmer
(800) 2-INVITRO
INVITRO INTERNATIONAL
Irvine

Bob Sullivan
760-931-2500
MAKENNA DELANEY & SULLIVAN
Carlsbad
IRVINE – July 7, 1998 – InVitro International, (OTC: INVI) announced that its quarter ended June 30, 1998, produced revenues of $138,600. This is the Company’s third consecutive quarter in which revenues and cash have grown. President and CEO, W. Richard Ulmer, stated “INVI’s unaudited cash and revenues in the most recent quarter once again met budget and showed a small increase. Profit and loss results are not yet available, however, exclusive of non-cash charges, our fiscal quarter should be near break even. These results reinforce management’s view that the Company has made good progress toward being able to stand alone and make us an even more attractive merger prospect.”

Regarding possible merger, Ulmer revealed that INVI’s target company, Miragen, has continued steps toward commercializing its patented Antibody Profiling identification technology. Recently, Miragen signed a licensing agreement with Ag Research of New Zealand, a combined private and government organization, to commit in excess of half a million dollars over the next twelve months to gather data in support of the antibody profile technology. The objective of this investment is to establish traceability of New Zealand sheep and cattle.

Currently, Miragen’s head of science, Dr. Thomas Unger, is in Calgary, Canada as an invited speaker to the Beef Improvement Federation. He is addressing the potential application of the antibody profile technology for use in identifying and tracing beef sold in North America. Despite these encouraging signs, any finalization of merger between Miragen and InVitro must await completion of either company’s planned financing.

InVitro International is engaged in the development, manufacture, and sale of proprietary, non-animal toxicity testing products and services that ensure the safekeeping of humans and the environment, and that minimize animal testing in commercial and academic enterprise.

Certain information in this document includes “forward-looking statements” within the meaning of applicable securities laws. In addition, from time to time the Company or its executive officers have made or may make forward-looking statements, orally or in writing, that involve substantial risks and uncertainties. Actual results could differ materially from those projected or suggested by forward-looking statements as a result of a variety of factors and conditions including, but not limited to, the ability of the Company to continue as a going concern, market acceptance of new products and technologies, economic, competitive, governmental, and technological factors affecting the Company’s operations, markets, services, and prices, Year 2000 issues, litigation costs, unanticipated events and various other factors. The reader is specifically referred to disclosures contained in this document and in prior documents publicly disseminated by the Company.

INVITRO INTERNATIONAL SIGNS INVESTOR RELATIONS FIRM

Makenna Delaney & Sullivan, Inc. to assist the firm.
W. Richard Ulmer
(800) 2-INVITRO
INVITRO INTERNATIONAL
Irvine

Bob Sullivan
760-931-2500
MAKENNA DELANEY & SULLIVAN
Carlsbad

IRVINE — June 8, 1998 – InVitro International, (OTC Bulletin Board: INVI) announced today that it has signed Makenna Delaney & Sullivan, Inc. to assist the firm with investor relations, capital formation, and related materials. InVitro has publically announced its intention to merge with entities in related technology fields, and has specifically targeted Miragen, Inc. Miragen, Inc. has developed a cost-effective, patented, biologically based identification system for use in several markets, including human clinical laboratories, animal, forensic, educational, and environmental applications.

For more than nine years, Makenna Delaney & Sullivan has specialized in investor relations, venture packaging, equity financing, strategic marketing, financial documentation, and corporate identity services. MDS is a nationally recognized leader in business document production and investor relations with a successful track record of assisting clients in their quest for capital.

InVitro International is engaged in the development, manufacture and sale of quality, proprietary preventive products and services to ensure the safekeeping of humans and the environment, and to minimize animal testing in commercial and academic enterprise.

InVitro International offers experience and consulting from what may be the world’s largest data base of NON-ANIMAL ocular and dermal test results; this offering is part of INVI’s Irritection Assay Systemr (IAS) and Corrositexr Assay methods. The IAS is a plate reader based computer driven upgrade from the former Eytex/Skintex methodology; it has been widely accepted over the past two years and has helped reduce industry costs when testing for safety and efficacy of ocular, skin care, personal care, and chemical products. InVitro International offers industry a series of services, including protocol development, customized contract testing services, and direct kit sales in support of product claims or workplace safety. The Irritection Assay System is well suited for choosing new formulations as well as testing final or competitive products. IAS helps cut time and costs out of new product development cycles.

Certain information in this document includes “forward-looking statements” within the meaning of applicable securities laws. In addition, from time to time the Company or its executive officers have made or may make forward-looking statements, orally or in writing, that involve substantial risks and uncertainties. Actual results could differ materially from those projected or suggested by any forward-looking statements as a result of a variety of factors and conditions including, but not limited to, the ability of the Company to continue as a going concern, market acceptance of new products and technologies, economic, competitive, governmental, and technological factors affecting the Company’s operations, markets, services, and prices, significant disruptions caused by third parties’ failure to address Year 2000 issues, litigation costs, changes in the Company’s operations, unanticipated events and various other factors. The reader is specifically referred to disclosures contained in this document and in prior documents publicly disseminated by the Company.

INVITRO INTERNATIONAL REPORTS SECOND QUARTER RESULTS AND COMMENTS ON ANNUAL MEETING

Company Looks Forward with Cautious Optimism
Irvine, CA, May 5, 1998 — InVitro International’s (Bulletin Board Symbol “INVI”) second fiscal quarter, ended March 31, 1998, resulted with revenues of $135,744, an increase of 2% over the revenues of $133,272 for quarter ended December 31, 1997; net loss for the second quarter was $36,069 or .003¢ per share, a decrease of $ 21,700 compared to first quarter losses and 91% less than second quarter 1997 losses of $395,000, or .02¢ per share. Management anticipates that the losses will continue to narrow if revenues increase only slightly above their current rate.

President and Chief Executive Officer, W. Richard Ulmer, stated “INVI’s unaudited second quarter financial for the period ending March 31, 1998, again showed an increase in cash with slightly higher sales than in the first quarter(ended December 31, 1997); profit and loss results were very near break-even for this second quarter.” Most of the quarter’s loss is attributable to fiscal year end audit, and shareholder/ broker printing and mailing expenses.

In reviewing current opportunities for INVI, Ulmer indicated that the recent increase in Department of Transportation enforcement personnel appears to have spurred more interest in Corrositex® testing in the United States; in addition, INVI’s agents and partner laboratories in both Asia and Europe have developed several new business opportunities for the Company’s Irritection Assay System® during the last year. Ulmer commented, “InVitro International has demonstrated a mental toughness and shown its ability to stay on course under difficult circumstances; we continue to believe that we are ahead of our time both with the non-animal testing core business as well as with the infant safety and identification product, Guardian DNA.” He continued by saying, “with the November 1997 United Kingdom legislation preventing future new finished cosmetics from being tested on animals, there is potential for more demand for non-animal test methodologies such as INVI’s Irritection Assay System in its Ocular and Dermal forms.”

Finally, Ulmer noted that as had been mentioned in the recent 1997 Letter to Shareholder, the Company’s current plan of operation includes a continuing effort to find a suitable merger partner. There is no new news on that activity at this time.

InVitro’s annual shareholder’ meeting was held on April 17, 1998, at which five incumbent directors were re-elected.

InVitro International is engaged in the development, manufacture and sale of proprietary, non-animal toxicity testing products and services that ensure the safekeeping of humans and the environment, and that minimize animal testing in commercial and academic enterprise.

Certain information in this document includes “forward-looking statements” within the meaning of applicable securities laws. In addition, from time to time the Company or its executive officers have made or may make forward-looking statements, orally or in writing, that involve substantial risks and uncertainties. Actual results could differ materially from those projected or suggested by any forward-looking statements as a result of a wide variety of factors and conditions, including but not limited to, the ability of the Company to continue as a going concern, market acceptance of new products and technologies, economic, competitive, governmental and technological factors affecting the Company’s operations, markets, services and prices, significant disruptions caused by third parties failures to address the Year 2000 issues, litigation costs, changes in the Company’s operations, unanticipated events and various other factors. The reader is specifically referred to disclosures contained in this document and in prior documents publicly disseminated by the Company.

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS



Three months ended March 31 Six months ended March 31
1998 1997 1998 1997
(unaudited) Revenues $136,000 $164,000 $269,000 $423,000

Costs and expenses 172,000 567,000 363,000 1,346,000

Loss from operations (36,000) (403,000) (94,000) (923,000)

Other income 0 8,000 0 22,000

Net loss $(36,000) $(395,000) $(94,000) $(901,000)

Loss per common share $(0.003) (0.02) $(0.01) (0.06)

Weighted average common
shares outstanding 14,028,300 14,023,300



Condensed Consolidated Balance Sheet
(unaudited) March 31, March 31, 1998 1997

Cash and cash equivalents $56,000 54,000

Other current assets 566,000 584,000

Total current assets 622,000 638,000

Noncurrent assets 204,000 255,000

Total assets $826,000 $893,000

Current liabilities $199,000 $169,000

Shareholders' equity 627,000 724,000

Total liabilities & equity $826,000 893,000








PRESIDENT’S LETTER

To Our Shareholders: InVitro International finished the 1997 fiscal year by recording its lowest quarterly loss since becoming a public company in 1991. The loss for the quarter ended September 30, 1997, was $232,000, or $0.01 per share, compared to a loss of $568,000, or $0.04 per share in the quarter ended September 30, 1996. Our loss for the full 1997 fiscal year was $1,331,000, or $0.09 per share, compared to a loss of $1,898,000, or $0.15 per share in fiscal 1996.

As our shareholders are aware from prior announcements, InVitro has experienced significant financial difficulties primarily as a result of low sales volume. Erosion in demand for our non-animal safety testing alternatives continued in fiscal 1997 as revenues declined to $720,000 from $1,063,000 in fiscal 1996. To maintain the Company’s survival, operations have been significantly downsized during the last three years by staff reductions and other decreases in operating expenses. The Company’s plan of operation is to seek a suitable merger partner in an effort to preserve and hopefully enhance shareholder value. InVitro is a clean public company, free of debt, with a diversified shareholder base that should be attractive to an appropriate merger candidate.

For the present, we have been able to maintain and preserve the Company’s core business while merger possibilities are pursued. To compensate in part for sales staff reductions, we have added agents and partner laboratories that have been appointed and trained in Europe, Asia and the Unites States. With these changes and my agreement to defer temporarily a portion of the President’s salary, the most recent quarter ended December 31, 1997, showed a small increase in the Company’s cash position from operations as compared to September 30, 1997. This is the first time InVitro has experienced positive cash flow from operations in a fiscal quarter. If the Company can successfully maintain this position or the immediate future, your management is committed to preserving INVI’s core business and seeking new customers while continuing the search for a suitable merger partner.

Our preferred merger partner, Miragen Inc., to date has been unable to complete a transaction due to delays in obtaining additional financing. At the request of Miragen’s Board, I have agreed to serve on a part-time basis as Miragen’s Acting President and Chief Executive Officer. I believe this affords an excellent opportunity to assess Miragen’s potential and progress while it continues to pursue financing necessary for Miragen to become a viable merger prospect.

Notwithstanding my current role in Miragen, my topmost priority is to preserve INVI’s core business and to take any steps possible for INVI to attain the goal of standing on its own financially. As we maintain InVitro’s technology and core capabilities, the Company is impatiently waiting for government and industry to move toward non-animal testing. There are new glimmers of hope from time to time as, for example, November 1997 legislation passed in the United Kingdom that prohibits animal testing for new cosmetic products marketed in the U.K.

Thank you for your continued support. We encourage shareholders and friends of the Company to put pressure through your purchasing decisions on industries such as cosmetics, industrial chemicals, textiles, personal care products and petrochemical in support of non-animal safety testing methods. As always, I can be reached at 1-800-2-INVITRO, extension 260, if I can be of help or service.

INVITRO REPORTS YEAR ENDED FINANCIAL RESULTS

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
Year Ended September 30,
1997 1996
Revenues $720,000 $1,063,000
Costs and expenses 2,077,000 3,036,000
Loss from operations (1,357,000) (1,973,000)
Other income 26,000 74,000
Net loss $(1,331,000) $(1,899,000)
Loss per common share $(0.09) (0.15)
Weighted average common
shares outstanding 14,012,959 12,386,893
Condensed Consolidated Balance Sheet
September 30, September 30,
1997 1996

Cash and cash equivalents $54,000 $1,209,000
Other current assets 584,000 819,000
Total current assets 638,000 2,028,000
Noncurrent assets 255,000 387,000
Total assets $893,000 $2,415,000
Current liabilities $169,000 $351,000
Shareholders’ equity 724,000 2,064,000
Total liabilities & equity $893,000 $2,415,000

INVITRO INTERNATIONAL REPORTS THIRD QUARTER RESULTS

Company Announces Lowest Quarterly Loss and Expands Merger Options
Irvine, CA, August 15, 1997 — InVitro International (Symbol INVI) today reported results for its third quarter ended June 30, 1997. The net loss for the quarter was $198,000 ($0.02 per share), a 42% decrease compared to $341,000 ($0.03 per share) reported for the same period last year. Revenues for the quarter were $181,000 compared to $327,000 for the same quarter in fiscal 1996.

On Friday, June 13, 1997, the U.S. Environmental Protection Agency (EPA) issued the final approval for CORROSITEX® in the Federal Register as Solid Waste Method 1120. This method lists CORROSITEX as an approved test for characterizing dermal corrosivity for solid waste (40 CFR Parts 260, 264, 265, and 266). CORROSITEX is an in vitro test system that mimics the effect of corrosives on living skin while lowering testing costs and providing quicker results when compared to in vivo.

During the first five months of 1997, the Company announced it had entered into letters of intent to pursue merger negotiations with two other business entities. Negotiations as to the first proposed merger were terminated by mutual agreement and activities relating to a proposed merger with Miragen Inc. have been suspended unless Miragen obtains additional financing.

The Company’s management is currently negotiating a proposed merger with another business engaged primarily in the development and sale of natural gas resources, but a definitive merger proposal has not been executed. Management plans to pursue merger negotiations with any suitable prospective candidate.

The Company’s management anticipates that existing cash resources of InVitro are adequate to sustain its current business operations only through the end of September 1997, and that increases in internal sales revenue and /or additional capital investment, neither of which can be predicted at present, will be required for InVitro to have sufficient resources to sustain its operations thereafter. The Company’s management has determined that InVitro will be forced to cease active business operations, other than ongoing efforts to market Guardian DNA products held in inventory, should the Company fail to enter into a letter of intent or other agreement to merge with another business enterprise by approximately the end of August 1997.

InVitro International is engaged in the development, manufacture and sale of quality, proprietary preventive products and services to ensure the safekeeping of humans and the environment, and to minimize animal testing in commercial and academic enterprise.

The statements made in this press release contain certain forward looking statements within the meaning of section 27a of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934 that involve a number of risks and uncertainties, including the risk that InVitro may be unable to complete the proposed transaction. Actual events or results may differ from InVitro’s expectations. In addition, investors should be apprised of risk factors discussed from time to time in the Company’s filings with the Securities and Exchange Commission, including without limitation information set forth in Exhibit 99.1 filed with the Company’s Annual Report on Form 10-KSB for the fiscal year ended September 30, 1996.

INVITRO INTERNATIONAL REPORTS SECOND QUARTER RESULTS

Company Signs Merger Letter Of Intent With Miragen
Irvine, CA, May 15, 1997 — InVitro International (Symbol INVI) today reported results for its second quarter ended March 31, 1997. Revenues for the quarter were $164,000 compared to $260,000 for the same quarter in fiscal 1996. The net loss for the quarter declined by 15% to $395,000 ($0.02 per share), compared to $467,000 ($0.04 per share) reported for the same period last year.

“Despite disappointing core business sales results, we remain encouraged by the prospects for Guardian DNAÔ ,” said W. Richard Ulmer, president and CEO for InVitro International. Guardian DNA is the new three-part infant/child safety system that is visioned as a hospital replacement for newborn footprinting; it combines education, documentation and ultimately identification using DNA technology. “Several healthcare institutions are in the process of reviewing Guardian, and/or obtaining the necessary internal approvals, for possible implementation at their respective facilities,” Ulmer added.

On Tuesday, May 13, 1997, the Company signed a letter of intent to merge with Miragen, Inc. (Irvine, CA) in a transaction anticipated to provide current InVitro shareholders with 20% of the combined company’s common stock subject to certain adjustments based on business developments prior to a definitive agreement. The new merger opportunity immediately follows the end of negotiations with Shenyang International as a potential merger partner and is contingent upon due diligence examination (already in process), filing of the appropriate materials with the Securities and Exchange Commission and approval by the majority of InVitro shareholders, among other conditions. Assuming the proposed merger is successfully completed, the assets and business of Miragen will be acquired by InVitro and will include all of Miragen’s existing assets and proprietary rights relating to human and animal identification products and related technologies. “The synergy between the two companies is both financially and market-driven,” said Ulmer. “We believe that InVitro’s core technology combined with Miragen’s biological and identification products, which include Guardian DNA, address unique marketplaces, and allow us to provide better pricing opportunities to customers and prospects.”

At the close of business on Wednesday, May 14, 1997, InVitro’s securities were removed from The Nasdaq SmallCap Market for non-compliance with NASDAQ listing standards. The Company’s common stock will continue to be traded in the over-the-counter market and quoted on the NASD Electronic Bulletin Board.

Miragen develops, manufactures and sells biological identification and testing technologies used in hospitals, medical laboratories, animal identification, and forensics.

InVitro International is engaged in the development, manufacture and sale of quality, proprietary preventive products and services to ensure the safekeeping of humans and the environment, and to minimize animal testing in commercial and academic enterprise.

The statements made in this press release contain certain forward looking statements within the meaning of section 27a of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934 that involve a number of risks and uncertainties, including the risk that InVitro may be unable to complete the proposed transaction. Actual events or results may differ from InVitro’s expectations. In addition, investors should be apprised of risk factors discussed from time to time in the Company’s filings with the Securities and Exchange Commission, including without limitation information set forth in Exhibit 99.1 filed with the Company’s Annual Report on Form 10-KSB for the fiscal year ended September 30, 1996.

INVITRO INTERNATIONAL SIGNS MERGER LETTER OF INTENT

IRVINE, CA, March 3, 1997 — InVitro International (Nasdaq SmallCap Market Symbol “INVI”) today announced it has signed a letter of intent to merge with Shenyang International Inc. in a transaction where InVitro stockholders would retain 20% of the combined company’s common stock. The proposed transaction is subject, among other conditions, to additional due diligence investigations, approval by the board of directors for each of the parties, preparation and execution of a definitive merger agreement, filing and the effectiveness of a registration statement and proxy materials with the Securities and Exchange Commission, and approval by the majority vote of InVitro shareholders.

The Company currently anticipates the merger proposal will be presented to InVitro’s board for consideration before the end of March 1997.

Privately-held Shenyang International Inc. is a foreign holding company organized in the British Virgin Islands and owns 99% of ShenYang Holding Company (“SHC”). Organized in 1988 and based in the Liaoning Province of northeastern China, SHC operates four business divisions in mainland China with approximately 300 employees. SHC’s business operations include distribution of medical products, the manufacture and sale of computer systems, ownership and management of the Lan Hua Hotel in ShenYang city and development of international industrial trade. Among other products, SHC distributes medical scanning devices for General Electric and markets personal computer hardware and networking systems. SHC has operated profitably for the last five years, and its annual revenues have increased from $6.5 million in 1992 to more than $15 million currently.

InVitro International, organized in 1985, develops and markets proprietary in vitro assay systems to detect, predict and rank potential irritation and toxic levels of substances to humans and the environment and distributes child safety and identification products. Located in Irvine, California, the Company distributes its products throughout North America, Europe and the Pacific Rim. InVitro previously reported a net loss for the year ended September 30, 1996 of $1,899,000, or $.15 per share, on revenues of $1,063,000. Results for the most recent fiscal quarter ended December 31, 1996 were a net loss of $506,000, or $.04 per share, on $259,000 in net sales. At February 28, 1997, InVitro had 14,028,300 shares of common stock outstanding.

Assuming the proposed merger is successfully completed, InVitro has undertaken to reduce its existing business operations to eliminate negative cash flow and currently anticipates those operations will continue under the direction of InVitro’s management as a separate division or subsidiary of the combined enterprise.

The statements made in this press release contain certain forward looking statements within the meaning of section 27a of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934 that involve a number of risks and uncertainties, including the risk that InVitro may be unable to complete the proposed transaction. Actual events or results may differ from InVitro’s expectations. In addition, investors should be apprised of risk factors discussed from time to time in the Company’s filings with the Securities and Exchange Commission, including without limitation information set forth in Exhibit 99.1 filed with the Company’s Annual Report on Form 10-KSB for the fiscal year ended September 30, 1996.

INVITRO INTERNATIONAL REPORTS FIRST QUARTER RESULTS

Board Of Directors Defer Decision To Implement 1-For-10 Reverse Stock Split Recently Approved By Shareholders
IRVINE, CA, February 4, 1997 — InVitro International (NASDAQ Small Cap; INVI) today reported results for its first quarter ended December 31, 1996. Revenues for the quarter were $259,000 compared to $225,000 for the first quarter of the prior year, a 15% increase. The net loss for the current quarter was $506,000 or $.04 per share, compared to a net loss of $522,000 or $.04 per share reported for the same period of the previous year.

During its Annual Shareholders Meeting held on Friday, January 31, 1997, the Company also announced its Board will delay a decision whether and when to implement a 1-for-10 reverse stock split authorized at the meeting by a majority of shareholders. InVitro International’s Board of Directors will defer an implementation decision until the timing of revised NASDAQ rules are announced and the Board has had an opportunity to assess initial results from the GiftPax program for Guardian DNA. (Guardian DNA is the new three-part infant/child safety system being marketed directly to 3.7 million new mothers during calendar year 1997 via GiftPax/American Sampling, Inc.) “We should have a preliminary indication as to the level of sales we can expect from the GiftPax opportunity by the end of March,” stated W. Richard Ulmer, President and CEO for InVitro International.

InVitro International is engaged in the development, manufacture and sale of quality, proprietary preventive products and services to ensure the safekeeping of humans and the environment, and to minimize animal testing in commercial and academic enterprise.

Except for the historical information contained herein, the matters discussed in this news release are forward looking statements that involve risks and uncertainties, including the acceptance of new products, the impact of competitive products and pricing, and the management of growth. Please refer to the Company’s filings with the Securities and Exchange Commission for a summary of cautionary statements.

INVITRO INTERNATIONAL TO REACH NEARLY 4 MILLION NEW MOTHERS IN 1997 WITH GUARDIAN DNA

$1.8 Million In INVI Sales To Result From Every 1 Percent Who Decide To Buy
IRVINE, CA, December 18, 1996 — InVitro International (NASDAQ Small Cap; INVI) today reported results of operations for its fiscal year ended September 30, 1996. The net loss for fiscal 1996 was $1,899,000 ($0.15 per share) on revenues of $1,063,000 versus a net loss of $2,763,000 ($0.23 per share) on revenues of $1,137,000 in fiscal 1995, and is the lowest in the Company’s public history. Progress with regard to net financial results are attributable to cost controls implemented throughout the fiscal year, while maintaining fiscal 1995 sales levels.

President and CEO for InVitro International, W. Richard Ulmer stated “We are encouraged that annual sales remained virtually the same and that losses declined by nearly $1 million, despite the heavy fourth quarter investment to introduce Guardian DNAä, the new infant/child safety system. We remain enthusiastic regarding future prospects for Guardian and are pleased that our core technology has recently attracted several new and important customers, including Ingman Laboratories in Minneapolis, Minnesota and Sima-Labs International in Merrillville, Indiana. Additionally, InVitro recently installed its IrritectionÒ Assay System in two textile companies, one of which carries world-wide name recognition.”

The goal of Company-wide profitability previously forecasted for InVitro’s first quarter of fiscal 1997 will not be met. The delay is a function of the difficulty in predicting the timing and the level of acceptance for Guardian DNA. As reported earlier, the Company has teamed with GiftPax/American Sampling, Inc. to provide approximately 3.7 million new mothers during 1997 with information about Guardian DNA during their hospital stay and the ability to purchase it at a reduced price. The first shipment of redeemable Guardian brochures were delivered to hospitals nationwide in early December and the product fulfillment center is ready to begin processing orders. “We feel extremely confident that Guardian DNA will be a success as it reaches hundreds of thousands of new mothers in January, and each successive month throughout 1997,”remarked Ulmer. “We estimate that a mere 1% response rate over the course of the next 12 months will turn the corner for the Company financially. Given the positive acceptance levels predicted by internal market research among end users, we have every reason to remain excited.”

InVitro International is engaged in the development, manufacture and sale of quality, proprietary preventive products and services to ensure the safekeeping of humans and the environment, and to minimize animal testing in commercial and academic enterprise.

Except for the historical information contained herein, the matters discussed in this news release are forward looking statements that involve risks and uncertainties, including the acceptance of new products, the impact of competitive products and pricing, and the management of growth. Please refer to the Company’s filings with the Securities and Exchange Commission for a summary of cautionary statements.